Andrea Bisso: Exploring the T Cell Engagers in Autoimmune Diseases
Andrea Bisso, Senior Director of Scientific Alliances – Head of Europe, shared a post on Linkedin about a recent article by Ricardo Grieshaber-Bouyer, published in Nature Reviews Immunology, adding:
“T cell engagers in autoimmune diseases
A paper a day keeps brain decay away
Thursday 2 July 2026
Despite advances in immunology, achieving durable, drug-free remission in refractory autoimmune diseases remains elusive due to incomplete B cell depletion
in tissue sanctuaries.
This perspective highlights how T cell engagers – off-the-shelf, bispecific antibodies – harness potent T cell-dependent cellular cytotoxicity to achieve deep B cell eradication and an unprecedented immune reset.
Take-home messages
- TCEs redirect endogenous T cells to eliminate autoreactive B cells through T cell-dependent cellular cytotoxicity, combining CAR T-like potency with the convenience of an off-the-shelf biologic.
- More than 30 TCEs targeting CD19, CD20 and B cell maturation antigen (BCMA) are already in clinical development across systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, myasthenia gravis and other autoimmune diseases.
- Next-generation engineering focuses on improving the therapeutic index through optimized CD3 affinity, multispecific designs, conditional activation and subcutaneous administration.
Why this matters
- TCEs could shift treatment from long-term immune suppression to immune reset, while remaining repeatable, scalable and immediately available.
A Key challenges
- Can efficacy be maintained while further reducing cytokine release syndrome?
- Which B-cell target delivers the deepest and most durable remission?
- Which patients require complete immune reset versus controlled immune modulation?”
Title: T cell engagers in autoimmune diseases
Authors: Ricardo Grieshaber-Bouyer, Lei Wu, Georg Schett, Patrick A. Baeuerle
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session